Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMY8O0B)

Drug Name

CP-320626 Drug Info

Synonyms

CP-320626; UNII-FKX709RK3Q; FKX709RK3Q; CHEMBL99889; 5-CHLORO-1H-INDOLE-2-CARBOXYLIC ACID [1-(4-FLUOROBENZYL)-2-(4-HYDROXYPIPERIDIN-1YL)-2-OXOETHYL]AMIDE; 5-chloro-N-[(2S)-3-(4-fluorophenyl)-1-(4-hydroxypiperidin-1-yl)-1-oxopropan-2-yl]-1H-indole-2-carboxamide; YDCGVASFVACWKF-NRFANRHFSA-N; AC1L9GTI; 1H-Indole-2-carboxamide, 5-chloro-N-((1S)-1-((4-fluorophenyl)methyl)-2-(4-hydroxy-1-piperidinyl)-2-oxoethyl)-; 186430-23-9; SCHEMBL7234251; BDBM35346; DB03383; 1H-Indole-2-carboxamide, 5-chloro-N-(1-((4-fluorophenyl)methyl)-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 444746
CAS Number: CAS 186430-23-9
TTD Drug ID: DMY8O0B

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Candida Cytochrome P450 51 (Candi ERG11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[2]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[2]
Posaconazole	DMUL5EW	Aspergillosis	1F20	Approved	[3]
Ketoconazole	DMPZI3Q	Blastomycosis	1F22	Approved	[4]
Miconazole	DMPMYE8	Cutaneous candidiasis	1F23.14	Approved	[2]
Oxiconazole	DME7KRM	Tinea corporis	1F28.Y	Approved	[5]
Fluconazole	DMOWZ6B	Cryptococcal meningitis		Approved	[2]
Terconazole	DMJ13KI	Candidiasis	1F23	Approved	[6]
Bifonazole	DM3KN7V	Fungal infection	1F29-1F2F	Approved	[7]
Tioconazole	DMNYPGS	Onychomycosis	EE12.1	Approved	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Candida Cytochrome P450 51 (Candi ERG11)	TTTSOUD	CP51_CANAL	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. Drug Metab Dispos. 2007 Mar;35(3):493-500.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3	A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49 Suppl 1:2-6.
4	Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
5	Antifungal agents: mechanisms of action. Trends Microbiol. 2003 Jun;11(6):272-9.
6	Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9.
7	Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys. 2006 Nov 1;455(1):61-7.
8	Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):261-6.